Show simple item record

The role of continuous renal replacement therapy in the management of acute kidney injury associated with sinusoidal obstruction syndrome following hematopoietic cell transplantation

dc.contributor.authorRaina, Rupesh
dc.contributor.authorAbusin, Ghada A.
dc.contributor.authorVijayaraghavan, Prashant
dc.contributor.authorAuletta, Jeffery J.
dc.contributor.authorCabral, Linda
dc.contributor.authorHashem, Hasan
dc.contributor.authorVogt, Beth A.
dc.contributor.authorCooke, Kenneth R.
dc.contributor.authorAbu‐arja, Rolla F.
dc.date.accessioned2018-03-07T18:24:59Z
dc.date.available2019-05-13T14:45:24Zen
dc.date.issued2018-03
dc.identifier.citationRaina, Rupesh; Abusin, Ghada A.; Vijayaraghavan, Prashant; Auletta, Jeffery J.; Cabral, Linda; Hashem, Hasan; Vogt, Beth A.; Cooke, Kenneth R.; Abu‐arja, Rolla F. (2018). "The role of continuous renal replacement therapy in the management of acute kidney injury associated with sinusoidal obstruction syndrome following hematopoietic cell transplantation." Pediatric Transplantation 22(2): n/a-n/a.
dc.identifier.issn1397-3142
dc.identifier.issn1399-3046
dc.identifier.urihttps://hdl.handle.net/2027.42/142494
dc.description.abstractMaintaining fluid balance, preâ and postâ MAâ HCT is essential and usually requires frequent administration of diuretics. Hepatic sinusoidal obstructive syndrome is potentially lifeâ threatening, especially when associated with AKI and MOF. This study describes six patients who developed AKIâ associated SOS and diureticâ resistant FO who subsequently underwent CRRT using standardized management guidelines for fluid balance postâ HCT. Retrospective chart review was done for HCT patients between September 2011 and October 2013 at a tertiary care children’s hospital. Thirtyâ four patients underwent MAâ HCT in the study period. Six patients had SOS complicated by diureticâ resistant FO and underwent CRRT. Defibrotide was used in three patients. Median time on CRRT was 10.5 days. Sixtyâ six percent (N = 4 of 6) of patients had full resolution of SOS symptoms with a mortality rate of 34% (N = 2 of 6). Among patients who had full recovery of SOS symptoms, one patient developed AKI, endâ stage renal diseases and underwent kidney transplantation 34â months postâ HCT. Thus, of six included patients, two died and one developed ESRD with only 50% (N = 3 of 6) good outcome. Use of a standardized, evidenceâ based fluid balance protocol and early initiation of CRRT for HCTâ related AKI/SOS was associated with good outcomes.
dc.publisherWiley Periodicals, Inc.
dc.subject.othersinusoidal obstruction syndrome
dc.subject.otherhematopoietic cell transplant
dc.subject.otheracute kidney injury
dc.subject.othercontinuous renal replacement therapy
dc.subject.otherfluid overload
dc.titleThe role of continuous renal replacement therapy in the management of acute kidney injury associated with sinusoidal obstruction syndrome following hematopoietic cell transplantation
dc.typeArticleen_US
dc.rights.robotsIndexNoFollow
dc.subject.hlbsecondlevelPediatrics
dc.subject.hlbtoplevelHealth Sciences
dc.description.peerreviewedPeer Reviewed
dc.description.bitstreamurlhttps://deepblue.lib.umich.edu/bitstream/2027.42/142494/1/petr13139.pdf
dc.description.bitstreamurlhttps://deepblue.lib.umich.edu/bitstream/2027.42/142494/2/petr13139_am.pdf
dc.identifier.doi10.1111/petr.13139
dc.identifier.sourcePediatric Transplantation
dc.identifier.citedreferenceKizilbash SJ, Kashtan CE, Chavers BM, Cao Q, Smith AR. Acute kidney injury and the risk of mortality in children undergoing hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2016; 22: 1264 â 1270.
dc.identifier.citedreferenceCoppell JA, Richardson PG, Soiffer R, et al. Hepatic venoâ occlusive disease following stem cell transplantation: incidence, clinical course, and outcome. Biol Blood Marrow Transplant. 2010; 16: 157 â 168.
dc.identifier.citedreferenceSutherland SM, Byrnes JJ, Kothari M, et al. AKI in hospitalized children: comparing the pRIFLE, AKIN, and KDIGO definitions. Clin J Am Soc Nephrol. 2015; 10: 554 â 561.
dc.identifier.citedreferenceNaples JC, Skeens MA, Auletta J, et al. Anicteric venoâ occlusive disease after hematopoietic stem cell transplantation in children. Bone Marrow Transplant. 2016; 51: 135 â 137.
dc.identifier.citedreferenceSkeens MA, McArthur J, Cheifetz IM, et al. High variability in the reported management of hepatic venoâ occlusive disease in children after hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2016; 22: 1823 â 1828.
dc.identifier.citedreferenceGoldstein SL, Currier H, Graf C, Cosio CC, Brewer ED, Sachdeva R. Outcome in children receiving continuous venovenous hemofiltration. Pediatrics. 2001; 107: 1309 â 1312.
dc.identifier.citedreferenceWallhult E, Kenyon M, Liptrott S, et al. Management of venoâ occlusive disease: the multidisciplinary approach to care. Eur J Haematol. 2017; 98: 322 â 329.
dc.identifier.citedreferenceDidsbury MS, Mackie FE, Kennedy SE. A systematic review of acute kidney injury in pediatric allogeneic hematopoietic stem cell recipients. Pediatr Transplant. 2015; 19: 460 â 470.
dc.identifier.citedreferenceRajpal JS, Patel N, Vogel RI, Kashtan CE, Smith AR. Improved survival over the last decade in pediatric patients requiring dialysis after hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2013; 19: 661 â 665.
dc.identifier.citedreferenceSutherland SM, Goldstein SL, Alexander SR. The prospective pediatric continuous renal replacement therapy (ppCRRT) registry: a critical appraisal. Pediatr Nephrol. 2014; 29: 2069 â 2076.
dc.identifier.citedreferenceFlores FX, Brophy PD, Symons JM, et al. Continuous renal replacement therapy (CRRT) after stem cell transplantation. A report from the prospective pediatric CRRT Registry Group. Pediatr Nephrol. 2008; 23: 625 â 630.
dc.identifier.citedreferenceWonnacott R, Josephs B, Jamieson J. CRRT regional anticoagulation using citrate in the liver failure and liver transplant population. Crit Care Nurs Q. 2016; 39: 241 â 251.
dc.identifier.citedreferenceDalle JH, Giralt SA. Hepatic venoâ occlusive disease after hematopoietic stem cell transplantation: risk factors and stratification, prophylaxis, and treatment. Biol Blood Marrow Transplant. 2016; 22: 400 â 409.
dc.identifier.citedreferenceRichardson PG, Corbacioglu S, Ho VT, et al. Drug safety evaluation of defibrotide. Expert Opin Drug Saf. 2013; 12: 123 â 136.
dc.identifier.citedreferenceRichardson PG, Cooke KR, Krishnan AY. Strategies for the management of hepatic venoâ occlusive disease in patients undergoing bone marrow transplant. Clin Adv Hematol Oncol. 2015; 13 ( Suppl 12 ). http://www.hematologyandoncology.net/files/2016/02/CAHO-Dec-Supp-1.pdf.
dc.identifier.citedreferenceCarreras E, Diazâ Beya M, Rosinol L, Martinez C, Fernandezâ Aviles F, Rovira M. The incidence of venoâ occlusive disease following allogeneic hematopoietic stem cell transplantation has diminished and the outcome improved over the last decade. Biol Blood Marrow Transplant. 2011; 17: 1713 â 1720.
dc.identifier.citedreferenceBasu RK, Zappitelli M, Brunner L, et al. Derivation and validation of the renal angina index to improve the prediction of acute kidney injury in critically ill children. Kidney Int. 2014; 85: 659 â 667.
dc.identifier.citedreferenceMichael M, Kuehnle I, Goldstein SL. Fluid overload and acute renal failure in pediatric stem cell transplant patients. Pediatr Nephrol. 2004; 19: 91 â 95.
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.